The Study
From soluble uric acid to sodium urate crystal: immune metabolic inflammation driven by uric acid morphological transformation and mechanism-oriented therapy
This study is like a science teacher drawing a story on the board about how uric acid might turn into crystals and cause inflammation, based on lab experiments. It doesn't prove any of this happens in real people—it just suggests how it could work.
Analysis score
Maximum 5 for a narrative review.
Where the score came from
Uric acid is like a chameleon: when it's dissolved in your blood at normal levels, it helps protect your cells and keeps inflammation low. But when there's too much, it turns into tiny crystals that cause gout pain, and also messes up your metabolism, leading to diabetes and heart problems.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 51 / 100
Quality score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this explains why some people have high uric acid for years without gout, and why suddenly lowering it can cause a flare.
- 2At 200–400 µM, uric acid blocks CD38 to boost NAD+ and reduce inflammation; above 0.36 mmol/L, it forms crystals that trigger gout; amorphous urate (AMSU) is a non-crystalline form that may delay gout flares for years.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Frontiers in Immunology
Year
2026
Authors
Qianqian Yang, Yundong Xu, Jian Zhang, Niqing Xiao, Hongting Lu, Bingbing Chen, Bo Yang, Zhaohu Xie, Zhaofu Li
Related Content
Claims (6)
When uric acid levels in the blood exceed 0.36 mmol/L, crystals form in joint tissues.
At normal levels in the body, uric acid reduces inflammation and increases autophagy by blocking CD38, which maintains NAD+ and activates SIRT1, leading to decreased activation of NF-κB and NLRP3 inflammasomes.
Amorphous monosodium urate forms before crystalline monosodium urate in people with high uric acid levels and reduces immune system activation, resulting in a longer period without gout symptoms.
Chronically high levels of soluble uric acid reduce AMPK activity, damage mitochondria, and trigger insulin resistance via oxidative stress and IRS-1 serine phosphorylation, leading to metabolic syndrome and type 2 diabetes.
Monosodium urate crystals activate a specific cellular pathway involving TLR and NLRP3 proteins, leading to the release of IL-1β and a form of cell death called pyroptosis, which drives acute inflammation.
A sudden drop in blood uric acid levels causes acute gout flares due to physical changes in urate crystals or temporary changes in immune and metabolic signaling, not just because new crystals form.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.